Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | AKT2 | P31751 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 16/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19589423 | 0.85 | ROCK2 (0.44) | TRPA1AKT1AKT2ROCK2ROCK1 | |
| SCHEMBL6520649 | 0.82 | AKT2 (0.50) | AKT1AKT2ROCK2ROCK1BCL2L1 | |
| SCHEMBL30332929 | 0.82 | DPP4 (0.55) | TRPA1AKT1AKT2ROCK2ROCK1 | |
| SCHEMBL8689398 | 0.76 | SIGMAR1 (0.46) | AKT1AKT2ROCK2ROCK1BCL2L1 | |
| SCHEMBL105445 | 0.76 | AKT1 (0.55) | TRPA1AKT1AKT2ROCK2ROCK1 | |
| SCHEMBL28552255 | 0.75 | AKT2 (0.72) | AKT1AKT2ROCK2 | |
| SCHEMBL30823568 | 0.75 | AKT2 (0.59) | AKT1AKT2ROCK2ROCK1 | |
| SCHEMBL30823569 | 0.75 | AKT2 (0.59) | AKT1AKT2ROCK2ROCK1 | |
| SCHEMBL18685194 | 0.73 | ROCK2 (0.54) | ROCK2ROCK1 | |
| SCHEMBL17030742 | 0.73 | TRPA1 (0.56) | TRPA1AKT1AKT2ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| WO-2003051906-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | TRPA1 4074/4885AKT1 29/4885AKT2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.